Clinical Trials Logo

Filter by:
NCT ID: NCT01629732 Withdrawn - Hepatitis C Virus Clinical Trials

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

Start date: March 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effectiveness of BMS-986094 and Daclatasvir (DCV) when given in combination with or without Ribavirin

NCT ID: NCT01628055 Withdrawn - Ischemic Stroke Clinical Trials

IVIG in Acute Ischemic Stroke: A Pilot Study

IVIG/AIS
Start date: March 2013
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the ability of IVIG to affect the rate of progression of brain ischemia, as evidenced by neuroimaging. The results of an ongoing epidemiological study indicate that patients with primary immunodeficiency (PID) on IVIG replacement therapy have an overall prevalence of stroke that is 5 times less than in the general population. Even more striking is the absence of stroke in IVIG-treated PID patients over 65, while in the same general population age group the stroke prevalence goes up to 8.1%. This suggests that the degree of stroke protection correlates with the length of IVIG treatment, since older PID patients have been treated with IVIG significantly longer than younger ones.

NCT ID: NCT01627925 Withdrawn - Clinical trials for Upper Airway Obstruction

Safety Study of Positive Airway Pressure Via a Nasal Mask in Obese Patients

Start date: June 2012
Phase: Phase 3
Study type: Interventional

Upper airway obstruction (UAO) is a frequently occurring complication during induction of general anesthesia. The American Society of Anesthesiologist (ASA) closed claim analysis of anesthesia complications indicate that a difficult airway is one of the most challenging scenarios continuously facing anesthesia providers. The mechanism of UAO during anesthesia has not been well understood. Posterior displacement of soft palate, tongue and epiglottis are believed to be the primary contributing factors. Obesity is well known to be an essential characteristic which reflects propensity to UAO. The mechanism of UAO during anesthesia shares many similarities with the upper airway obstruction observed during obstructive sleep apnea (OSA). Nasal continuous positive airway pressure (nCPAP) via nasal mask (NM) can maintain the airway patent with near 100% success in patients with OSA. Obesity is a major risk factors for obstructive sleep apnea and obese patients have a higher prevalence of UAO during anesthesia. Therefore, the investigators hypotheses that nCPAP should eliminate airway obstruction in obese patients under anesthesia. The investigators propose to test this hypothesis and determine the efficacy of nCPAP on maintaining airway patency in obese patients who require general anesthesia.

NCT ID: NCT01627548 Withdrawn - PTSD Clinical Trials

UCLA Couples Counseling for Combat Veterans

CCCV
Start date: January 2012
Phase: N/A
Study type: Interventional

A pilot intervention of an existing intervention adapted for the returning warfighter population: a couples treatment for PTSD, Structured Approach Therapy (SAT), which emphasizes reducing the PTSD avoidance/numbing symptoms that are corrosive in families.

NCT ID: NCT01626313 Withdrawn - Clinical trials for Family Communications

UCLA FOCUS Family Resiliency Training Research Study

FOCUS
Start date: December 2011
Phase: N/A
Study type: Interventional

The study will examine the effectiveness of an eight session, manualized individual family resiliency training (IFRT) for families with one OEF/OIF/OND veteran in promoting better family communication relating to return to post military life.

NCT ID: NCT01625793 Withdrawn - Hepatitis C Clinical Trials

Inflammation, Stress & Social Behavior: Using Ecological Assessments & Model Systems to Enhance Relevance to Health Outcomes

Start date: June 2012
Phase: N/A
Study type: Interventional

The current study has been designed to identify behavioral and physiological mechanisms through which positive social connectivity (PCS) and negative social processes (NSP) interact with psychosocial stress to promote resilience in the context of illness. The investigators model inflammation (a central element of all disease states) through the use of treatment with interferon (IFN)-alpha, which provides a standardized regimen of chronic cytokine exposure known to produce profound behavioral disturbances, including depression, fatigue and sickness, in a high percentage of individuals. To objectively assess social processes, the current project will employ the Electronically Activated Recorder (EAR), which periodically and unobtrusively records snippets of ambient sounds in people's momentary environments. To objectively assess behavioral and physiological responses to psychosocial stress the current project will employ the Trier Social Stress Test (TSST), a standardized laboratory stressor known to reliably activate behavioral, neuroendocrine and inflammatory responses. These novel methodologies and model systems will be employed to test the hypotheses that (a) pre-existing affiliative and prosocial behavior will promote resilience in the context of chronic inflammation and that (b) —conversely—chronic inflammation will reduce affiliative and prosocial behavior via effects on stress reactivity, neuroendocrine function and sleep. Finally, it will explore (c) the potential mediating role of stress physiology. To test these hypotheses, 110 subjects with chronic hepatitis C virus infection will be randomized to receive treatment with pegylated IFN-alpha plus ribavirin or to postpone treatment for 6 weeks: 55 subjects at University of Arizona and 55 subjects at Emory University. Prior to randomization and 6 weeks later all subjects will be evaluated with the EAR and sleep actigraphy in their home environments and will undergo TSST and 14 hour diurnal neuroendocrine and immune measurement.

NCT ID: NCT01624493 Withdrawn - Ovarian Cancer Clinical Trials

BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients

Start date: October 2012
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial will determine the recommended dose and activity of BNC105P for patients with partially platinum sensitive ovarian cancer in first or second relapse.

NCT ID: NCT01623388 Withdrawn - Type I Diabetes Clinical Trials

Epigenetic Modifications of Diabetes Mellitus Type I

Start date: January 2013
Phase: N/A
Study type: Observational

This research is being done to find out if significant changes in blood glucose cause bad outcomes in patients with diabetes.

NCT ID: NCT01623232 Withdrawn - Aged Clinical Trials

MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly

CCTA #0005
Start date: October 2012
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1,2 randomized, double-blind, multi-center, clinical trial, in participants aged 65 years and older, evaluating the immunogenicity and safety of a water-in-oil emulsion adjuvant (MAS-1 adjuvant, Mercia Pharma, Inc, Scarsdale, NY) combined with each of the three reduced HA antigen dose levels of trivalent influenza virus vaccine compared with licensed, unadjuvanted, standard dose trivalent virus (TIV). Immunogenicity for each of the three viral strains (A/H1N1, A/H3N2, and B virus) in the concurrent influenza seasonal vaccine will be assessed.

NCT ID: NCT01622595 Withdrawn - Aspergillosis Clinical Trials

UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients

Start date: November 2009
Phase: N/A
Study type: Observational

OBSERVATIONAL STUDY OF INFECTIOUS COMPLICATIONS IN CANCER PATIENTS